bidridistrogene xeboparvovec (SRP-9003) / Sarepta Therap 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bidridistrogene xeboparvovec (SRP-9003) / Sarepta Therap
NCT06246513: A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4 (EMERGENE)

Recruiting
3
15
US
SRP-9003, scAAVrh74.MHCK7.hSGCB, bidridistrogene xeboparvovec, Glucocorticoid, Prednisone or equivalent
Sarepta Therapeutics, Inc.
Limb-girdle Muscular Dystrophy
01/25
11/29
NCT03652259: Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)

Active, not recruiting
1/2
6
US
SRP-9003, LGMD2E vector, bidridistrogene xeboparvovec
Sarepta Therapeutics, Inc.
Limb-Girdle Muscular Dystrophy, Type 2E
02/27
02/27
NCT05876780: A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)

Active, not recruiting
1
6
US
SRP-9003, scAAVrh74.MHCK7.hSGCB
Sarepta Therapeutics, Inc.
Limb Girdle Muscular Dystrophy
08/28
08/28

Download Options